Study to Examine Efficacy and Safety of Rituximab in Participants With Rheumatoid Arthritis
Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
This Phase IV post-marketing, non-interventional, open label, non-comparative and prospective
study will examine the efficacy and safety of rituximab in participants who had previously
received rituximab in terms of everyday medical practice. Efficacy and safety of rituximab
will be determined 24 weeks after receiving the first infusion, 24 weeks after the second
infusion repeated courses of treatment (if the participants receive another course of
rituximab) and 24 weeks after the third infusion repeated courses of treatment (if the
participants receive third course of rituximab). Protocol does not specify the criteria for
initiation of treatment with rituximab and procedure of the infusion of rituximab. Rituximab
will be administered at the discretion of treating physician according to approved label.